FDA Approves Breakthrough Gene Therapy for Genetic Deafness (fda.gov)

• First clinical gene therapy for auditory genetic disorders.
• Direct correction of OTOF gene deficiency.
• Advances precision medicine for sensory restoration.

"The US FDA has granted approval for the first-ever gene therapy designed to treat hereditary hearing loss, specifically targeting the DFNB9 mutation. By delivering a functional OTOF gene directly to the inner ear, the treatment aims to restore auditory function in patients who previously had no viable options. This clinical milestone validates the use of viral vectors for targeted sensory tissue repair and paves the way for broader applications in treating congenital genetic deficits through precision genomic medicine."